Sambhavi Puri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sambhavi Puri has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Wolozin
Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, USA
4 shared publications - Alain Ibáñez de Opakua
German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany
2 shared publications - Debdeep Chatterjee
Department of Physics, Chemistry and Biology, Linköping University, SE-581 83 Linköping, Sweden
2 shared publications - Jenna L. Libera
Department of Anatomy and Neurobiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA
2 shared publications - Markus Zweckstetter
German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen, Germany
2 shared publications - Pijush Chakraborty
Department for NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences
2 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
m6A Dynamics in Alzheimer’s Disease: Methodological Approaches and Biological Insights
Alzheimer’s disease (AD) is characterized by progressive cognitive decline, amyloid β accumulation, tau pathology, and neuroinflammation. Emerging evidence indicates that N6-methyladenosine (m6A), the most abundant internal mRNA modification, is altered in AD and may contribute to disease pathogenesis. In this review, we summarize current findings on m6A regulation in human AD patient samples and mouse model systems, highlighting both consistent trends and notable discrepancies across studies. Differences in RNA source, analytical platform, and disease context contribute to the variability reported in total m6A abundance. Many m6A changes do not appear to broadly alter transcript or protein abundance, but several studies identify specific methylation events that can influence translation, synaptic function, and AD-related phenotypes in experimental models. Together, these observations suggest that m6A is a dynamic regulatory layer in AD which merits further investigation.
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open Accessm6A Dynamics in Alzheimer’s Disease: Methodological Approaches and Biological Insights
Alzheimer’s disease (AD) is characterized by progressive cognitive decline, amyloid β accumulation, tau pathology, and neuroinflammation. Emerging evidence indicates that N6-methyladenosine (m6A), the most abundant internal mRNA modification, is altered in AD and may contribute to disease pathogenesis. In this review, we summarize current findings on m6A regulation in human AD patient samples and mouse model systems, highlighting both consistent trends and notable discrepancies across studies. Differences in RNA source, analytical platform, and disease context contribute to the variability reported in total m6A abundance. Many m6A changes do not appear to broadly alter transcript or protein abundance, but several studies identify specific methylation events that can influence translation, synaptic function, and AD-related phenotypes in experimental models. Together, these observations suggest that m6A is a dynamic regulatory layer in AD which merits further investigation.
- Open Access
Loss of age-associated increase in m 6 A-modified RNA contributes to GABAergic dysregulation in Alzheimer’s disease
Dysregulated RNA metabolism is a significant feature of Alzheimer’s disease (AD), yet how post-transcriptional RNA modifications like N 6 -methyladenosine (m 6 A) are altered in AD is unknown. Here, we performed d eamination a djacent to R NA modification targets (DART-seq) on human dorsolateral prefrontal cortices to assess changes in m 6 A with nucleotide resolution. In non-AD brains, m 6 A sites increased with age, predominantly within the 3′UTR of transcripts encoding tripartite synapse proteins. In contrast, AD brains lost the age-associated m 6 A site increase and exhibited global hypomethylation of transcripts, including MAPT and APP . Hypomethylated genes involved with GABAergic signaling, glutamate transport, and ubiquitin-mediated proteolysis exhibited reduced expression, connecting m 6 A to synaptic excitotoxicity and disrupted proteostasis in AD. Site-specific m 6 A levels were linked with GABRA1 expression and protein levels, but this relationship was abolished in AD. Our findings provide insight into post-transcriptional mechanisms of dysregulated RNA metabolism in AD that are related to aging and GABAergic regulation. HIGHLIGHTS: With age, the number of m 6 A sites increases among Control cases (lacking AD pathology) but remains unchanged in AD cases. Transcripts are globally hypomethylated in AD cases. Hypomethylation is linked to decreased mRNA expression of transcripts related to synaptic and proteostatic function in AD. 3’UTR-localized m 6 A sites lack typical association with transcript metabolism of GABRA1 in AD. Graphical
Open AccessLoss of age-associated increase in m 6 A-modified RNA contributes to GABAergic dysregulation in Alzheimer’s disease
Dysregulated RNA metabolism is a significant feature of Alzheimer’s disease (AD), yet how post-transcriptional RNA modifications like N 6 -methyladenosine (m 6 A) are altered in AD is unknown. Here, we performed d eamination a djacent to R NA modification targets (DART-seq) on human dorsolateral prefrontal cortices to assess changes in m 6 A with nucleotide resolution. In non-AD brains, m 6 A sites increased with age, predominantly within the 3′UTR of transcripts encoding tripartite synapse proteins. In contrast, AD brains lost the age-associated m 6 A site increase and exhibited global hypomethylation of transcripts, including MAPT and APP . Hypomethylated genes involved with GABAergic signaling, glutamate transport, and ubiquitin-mediated proteolysis exhibited reduced expression, connecting m 6 A to synaptic excitotoxicity and disrupted proteostasis in AD. Site-specific m 6 A levels were linked with GABRA1 expression and protein levels, but this relationship was abolished in AD. Our findings provide insight into post-transcriptional mechanisms of dysregulated RNA metabolism in AD that are related to aging and GABAergic regulation. HIGHLIGHTS: With age, the number of m 6 A sites increases among Control cases (lacking AD pathology) but remains unchanged in AD cases. Transcripts are globally hypomethylated in AD cases. Hypomethylation is linked to decreased mRNA expression of transcripts related to synaptic and proteostatic function in AD. 3’UTR-localized m 6 A sites lack typical association with transcript metabolism of GABRA1 in AD. Graphical
- Open Access
- 8 April 2025
- Published by EMBL-EBI
Cryo electron micrographs of GSK3β phosphorylated tau fibrils
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.
- 8 April 2025
- Published by EMBL-EBI
Open AccessCryo electron micrographs of GSK3β phosphorylated tau fibrils
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.
- Top Cited PapersOpen Access
- 18 December 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (52)
GSK3β phosphorylation catalyzes the aggregation of tau into Alzheimer's disease-like filaments
The pathological deposition of proteins is a hallmark of several devastating neurodegenerative diseases. These pathological deposits comprise aggregates of proteins that adopt distinct structures named strains. However, the molecular factors responsible for the formation of distinct aggregate strains are unknown. Here, we show that the serine/threonine kinase GSK3β catalyzes the aggregation of the protein tau into Alzheimer’s disease (AD)-like filaments. We demonstrate that phosphorylation by GSK3β, but not by several other kinases, promotes the aggregation of full-length tau as well as enhances phase separation into gel-like condensate structures. Cryoelectron microscopy further reveals that the fibrils formed by GSK3β-phosphorylated tau adopt a fold comparable to that of paired helical filaments isolated from the brains of AD patients. Our results elucidate the intricate relationship between posttranslational modification and the formation of tau strains in neurodegenerative diseases.
- 18 December 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (52)
Top Cited PapersOpen AccessGSK3β phosphorylation catalyzes the aggregation of tau into Alzheimer's disease-like filaments
The pathological deposition of proteins is a hallmark of several devastating neurodegenerative diseases. These pathological deposits comprise aggregates of proteins that adopt distinct structures named strains. However, the molecular factors responsible for the formation of distinct aggregate strains are unknown. Here, we show that the serine/threonine kinase GSK3β catalyzes the aggregation of the protein tau into Alzheimer’s disease (AD)-like filaments. We demonstrate that phosphorylation by GSK3β, but not by several other kinases, promotes the aggregation of full-length tau as well as enhances phase separation into gel-like condensate structures. Cryoelectron microscopy further reveals that the fibrils formed by GSK3β-phosphorylated tau adopt a fold comparable to that of paired helical filaments isolated from the brains of AD patients. Our results elucidate the intricate relationship between posttranslational modification and the formation of tau strains in neurodegenerative diseases.